Tsonaka, Roula
Seyer, Alexandre
Aartsma-Rus, Annemieke
Spitali, Pietro
Funding for this research was provided by:
FP7 Health,European Union (305121, 305121)
Duchenne Parent Project
Article History
Received: 21 September 2020
Accepted: 7 June 2021
First Online: 21 June 2021
Competing interests
: Roula Tsonaka, Annemieke Aartsma-Rus and Pietro Spitali report being employed by the Leiden University Medical Center (LUMC) and receive salary by the LUMC. LUMC has patents on exon skipping, which were licensed to BioMarin and subsequently sublicensed to Sarepta. As co-inventor of some of these patents, Dr. Aartsma-Rus is entitled to a share of royalties. Pietro Spitali has served as ad-hoc consultant for Esperare, Summit PLC, Biomarin, Solid Bio, Bioclinica B.V., Marathon Biopharma, Astellas, Epirium Bio and Mantis therapeutics. He has served as in the scientific advisory board of Esperare, Epirium Bio and Summit PLC. Remuneration for these activities is paid to LUMC. A.A.-R. is also an ad hoc consultant for PTC Therapeutics, Sarepta Therapeutics, CRISPR Therapeutics, Summit PLC, Alpha Anomeric, BioMarin Pharmaceuticals, Eisai, Astra Zeneca, Global Guidepoint and GLG consultancy, Grunenthal, Wave and BioClinica, having been a member of the Duchenne Network Steering Committee (BioMarin) and being a member of the scientific advisory boards of ProQR and Philae Pharmaceuticals. Remuneration for these activities is paid to LUMC. LUMC also received speaker honoraria from PTC Therapeutics and BioMarin Pharmaceuticals and funding for contract research from Italpharmaco and Alpha Anomeric. Alexandre Seyer reports being employed by MedDay and receives salary by MedDay.